Internal Medicine, Hematology & Oncology · Indianapolis, IN
NPI
1295735058
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
8301 Harcourt Rd, Suite #200
Indianapolis, IN, 46260
Phone (317) 415-6600
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.0M
241,755 services
Medicare patients, 2024
1,032
Average age 74
Drug cost, 2024
$10.1M
2,714 prescriptions
Company payments, 2025
$436K
From 66 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ruemu E Birhiray was code J0185 (injection, aprepitant, 1 mg), 19,240 times for 33 patients. In total Ruemu E Birhiray billed 241,755 services in 140 codes, and Medicare paid $5.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-12-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0185 Injection, aprepitant, 1 mg | Office | 19,240 | 33 | $1.32 | $25K |
| J0897 Injection, denosumab, 1 mg | Office | 17,940 | 132 | $20.57 | $369K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,690 | 21 | $6.44 | $50K |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 6,350 | 13 | $44.74 | $284K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,719 | 48 | $0.09 | $238 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,700 | 24 | $15.32 | $41K |
| 36415 Venipuncture Blood Collection | Office | 2,380 | 702 | $8.61 | $20K |
| 85025 Blood Count | Office | 2,257 | 686 | $7.57 | $17K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,660 | 34 | $0.68 | $1,130 |
| 99214 Office E&M - Established | Office | 1,032 | 561 | $85.47 | $88K |
| 99215 Office E&M - Established | Office | 670 | 264 | $126.76 | $85K |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 585 | 82 | $70.11 | $41K |
| 96372 Injection Administration | Office | 549 | 185 | $9.77 | $5,363 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 488 | 15 | $0.07 | $35.21 |
| 96413 Chemotherapy Administration | Office | 467 | 71 | $88.97 | $42K |
By year: 2022 $4.2M for 192,326 services; 2023 $4.8M for 213,169 services; 2024 $5.0M for 241,755 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,380 | 702 | $8.61 | $20K |
| 85025 Blood Count | 2,257 | 686 | $7.57 | $17K |
| 81002 Clinical Chemistry | 127 | 31 | $3.33 | $423 |
Medicare prescription drug claims, 2024
In 2024, the drug Ruemu E Birhiray prescribed most often to Medicare patients was Anastrozole, with 624 prescriptions and refills. In total Ruemu E Birhiray wrote 2,714 Medicare prescriptions that cost $10.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 624 | 1,809 | 225 | $12K |
| Verzenio Abemaciclib | 143 | 143 | 16 | $2.1M |
| Tamoxifen Citrate Generic | 132 | 367 | 48 | $3,792 |
| Letrozole Generic | 115 | 321 | 43 | $2,953 |
| Gabapentin Generic | 108 | 210 | 38 | $1,480 |
| Revlimid Lenalidomide | 95 | 95 | 13 | $1.5M |
| Alendronate Sodium Generic | 76 | 216 | 25 | $389 |
| Eliquis Apixaban | 74 | 102 | 20 | $59K |
| Levothyroxine Sodium Generic | 62 | 133 | 22 | $540 |
| Potassium Chloride Generic | 60 | 86 | 23 | $490 |
| Imbruvica Ibrutinib | 52 | 52 | Under 11 | $917K |
| Ondansetron Odt Ondansetron | 49 | 49 | 26 | $454 |
| Dexamethasone Generic | 48 | 62 | 22 | $894 |
| Ondansetron Hcl Generic | 41 | 41 | 17 | $2,693 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 41 | 117 | 19 | $546 |
Brand drugs: 798 claims; generic drugs: 1,916 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ruemu E Birhiray $436K ($435K in general payments such as food, travel and fees and $1,102 for research) from 66 companies. The largest payer was Janssen Biotech, Inc. with $77K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 70 | $77K |
| Incyte Corporation INCY | 48 | $66K |
| AstraZeneca Pharmaceuticals LP AZN | 41 | $65K |
| GlaxoSmithKline, LLC. GSK | 35 | $40K |
| Lilly USA, LLC LLY | 19 | $26K |
| Exelixis Inc. EXEL | 15 | $21K |
| Stemline Therapeutics Inc. | 17 | $20K |
| BeOne Medicines USA, Inc. ONC | 12 | $18K |
| Abbvie Inc. ABBV | 18 | $17K |
| Sanofi US Services Inc. SNY | 8 | $15K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.